A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)
Phase 2
Completed
- Conditions
- End-Stage Renal Disease (ESRD)
- Interventions
- Drug: EPN-701 (Oral)
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Epizon Pharma, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05285787
- Locations
- 🇺🇸
Southeastern Clinical Research Institute, LLC, Augusta, Georgia, United States
© Copyright 2025. All Rights Reserved by MedPath